NovaScreen Receives Wyeth Contract for High Throughput Screen
NovaScreen Biosciences Corporation, a Caliper Life Sciences Company, announced that Wyeth Pharmaceuticals, a division of Wyeth, has selected NovaScreen to conduct a high-throughput screening (HTS) campaign. As a result, NovaScreen will screen 500,000 compounds against an inflammatory target.
The HTS campaign combines NovaScreen's kinase profiling expertise with Caliper's LabChip(R) 3000 microfluidic screening platform, which utilizes electrophoretic separation of assay components to provide analytical quality data that is highly reproducible.
Most read news
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.